ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Avapritinib

Also written as “avapritinib” and “CS3007 (BLU-285)”.

Its studies are mostly in Gastrointestinal Stromal Tumors · Mastocytosis, Systemic · Leukemia, Mast-Cell · Central Nervous System Neoplasms, led by 2 companies.

Drug pageAvapritinib: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 29, 202110 company-led studies, 2 open or runningNext primary completion: Jun 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only92 open or runningphase 4since Mar 29, 2021Jul 23, 2015Jun 23, 2027phase 2 · NCT03731260
CStone Pharmaceuticals10 open or runningphase 2since Dec 9, 2019Dec 9, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CStone Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named avapritinibINNProposed as its International Nonproprietary Name in WHO's List 117
  2. Dec 9, 2019First study: phase 2 study in Gastrointestinal Stromal TumorsFirst studyNCT04254939 · 65 enrolled · China

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

The one study CStone Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04254939Gastrointestinal Stromal Tumors · China2CompletedApr 30, 202065

How it is read

Names in the registry

  • “Avapritinib”, 7 entries
  • “avapritinib”, 2 entries
  • “CS3007 (BLU-285)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.